Call today to speak with a live representative:
1-888-BAXTER9
(888-229-8379)
Operated by a third party.
The Baxter Insurance Assistance Helpline is ready to help, at 1-888-BAXTER9. It's toll free, easy to use and available to everyone. You can talk to a live person about your insurance questions as well as FACTOR ASSIST. They can assist you with:
Call 1-888-BAXTER9 today.
Life is easier with a safety net. FACTOR ASSIST provides just that — It's a program that lets you earn credits toward factor therapy, like ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], in the event you reach a lifetime cap or lose insurance coverage.
FACTOR ASSIST is available to all patients currently using a Baxter hemophilia therapy. Enrollment into FACTOR ASSIST does not cost you anything. Simply call the Baxter Insurance assistance Helpline at 1-888-BAXTER9 (1-888-229-8379, operated by a third party) to enroll today. Why be without it?
Indications:
ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] is indicated in hemophilia A (classical hemophilia) for the prevention and control of bleeding episodes and for perioperative management of patients with hemophilia A.
ADVATE is not indicated for the treatment of von Willebrand’s disease.
Important Safety Information:
Let your doctor know if you have had any previous allergic reactions to other factor VIII products or mouse or hamster proteins.
The most common related adverse reactions observed during the ADVATE clinical studies include: strange taste in mouth, headache, dizziness, and redness in the face.
There is a possibility that you can have an allergic reaction to ADVATE. Symptoms of an allergic reaction may include rash, hives, itching, tightness in throat or chest, difficulty breathing, feeling dizzy or light-headed, or a weak pulse. If you experience any of these symptoms, stop the infusion immediately and promptly contact your doctor.
Contact your doctor if you are not able to prevent or control bleeding episodes with your regular doses of factor VIII therapy.
